

Health Systems and Self-Reported Medication Adherence in Patients with Hypertension: A cross-sectional comparison of Jamaica and Colombia

Marshall Tulloch-Reid

`marshall.tullochreid@uwimona.edu.jm`

The University of the West Indies <https://orcid.org/0000-0003-3081-4630>

Selena Lewis

The University of the West Indies

Carene Lindsay

The University of the West Indies

Siyi Geng

University of Texas Southwestern Medical Center

Paola Lanza Paola Lanza

University of Texas Southwestern Medical Center

Jacqueline Duncan

The University of the West Indies

Trevor Ferguson

The University of the West Indies <https://orcid.org/0000-0002-2393-1452>

Patricio López-Jaramillo

Fundación Oftalmológica de Santander-Clinica Carlos Ardila Lulle (FOSCAL) <https://orcid.org/0000-0002-9122-8742>

Jose P Lopez-Lopez

Universidad de Santander (UDES) <https://orcid.org/0000-0001-8865-0929>

Farah Allouch

<https://orcid.org/0000-0002-0275-3423>

Lizheng Shi

Tulane University

Nadia Bennett

The University of the West Indies

Gregorio Sanchez-Vallejo

Universidad del Quindio

Gustavo Aroca

Jiang He

Article

Keywords:

Posted Date: September 5th, 2025

DOI: <https://doi.org/10.21203/rs.3.rs-7454001/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations:

There is **NO** conflict of interest to disclose.

Table 1 and 2 are available in the Supplementary Files section.

1 **Health Systems and Self-Reported Medication Adherence in Patients with**

2 **Hypertension: A cross-sectional comparison of Jamaica and Colombia**

3 Marshall K.Tulloch-Reid¹ Selena Lewis¹, Carene Lindsay¹, Siyi Geng², Paola Lanza²,
4 Jacqueline Duncan¹, Trevor Ferguson¹, Patricio Lopez-Jaramillo^{3, 4}, Jose Lopez-Lopez³, ,
5 Farah Allouch⁵, Lizheng Shi⁵, Nadia Bennett¹, Gregorio Sanchez-Vallejo⁶, Gustavo Aroca-
6 Martinez⁷, Jiang He².

7 ¹ The University of the West Indies, Mona, Jamaica

8 ² Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, Texas
9 75390, USA

10 ³ Masira Research Institute, Universidad de Santander (UDES), Bucaramanga, Colombia

11 ⁴ Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador

12 ⁵ Department of Epidemiology, Tulane School of Public Health and Tropical Medicine, Tulane
13 University, New Orleans, LA 70112, USA

14 ⁶ Fundación Cardiomet Cequin and Universidad del Quindío, Armenia, Colombia,

15 ⁷ Centro de Investigaciones en Ciencias de la Vida, Facultad de Ciencias de la Salud,
16 Universidad Simón Bolívar and Departamento de Nefrología, Clínica de la Costa,
17 Barranquilla, Colombia.

18

19

20 Corresponding Author:
21 Marshall Tulloch-Reid, MBBS, MPhil, DSc. FACE
22 Epidemiology Research Unit, Caribbean Institute for Health Research,
23 7 Ring Road, Kingston 7
24 Jamaica
25 Telephone (876) 927 2471
26 Fax (876) 9272984
27 Email: marshall.tullochreid@uwimona.edu.jm
28

Summary

What is known

- Hypertension control in Latin American and the Caribbean remains suboptimal
- Medication adherence is an important determinant of blood pressure control and can be affected by several factors including systems of care

What this study adds

- We found that Jamaican patients with hypertension were 7 times more likely to report low or medium self-reported medication adherence than Colombian patients.
- Country differences in medication adherence were not explained by known sociodemographic factors or patient health care experiences
- Use of electronic health records, a national health insurance policy and public private partnerships such as contracting clinical services through physicians' offices may be important health system differences that explain country differences in medication adherence

30 **Abstract**

31 Robust health care systems can support medication adherence as a strategy to improve blood
32 pressure control in Latin America and the Caribbean. The Caribbean and South American
33 Team Based Strategies to Control Hypertension (CATCH) study, conducted in Jamaica and
34 Colombia, allowed us to examine how differing health systems (Jamaica – manual, paper-
35 based, government run vs Colombia - electronic systems utilizing government contracted
36 providers) influenced self-reported antihypertensive medication adherence among
37 hypertensive patients. A total of 576 hypertensive patients from 14 primary care clinics
38 completed telephone interviews between August 2021 and February 2022 during the COVID-
39 19 pandemic. Self-reported medication adherence was measured using the IMPACTS-MAS
40 questionnaire and patients categorized as having high (6), medium (5-5.5) or low (<5)
41 adherence based on score. Country was used as a proxy for health systems in multivariable
42 logistic regression models with medium/low adherence as the primary outcome. Jamaican
43 patients were more likely to report medium/low adherence (49.3% vs 11.8% $p < 0.001$). In
44 Colombia, younger (< 60 years) and never married patients reported more medium/low
45 adherence. Jamaican patients experienced longer wait times for services but were more likely
46 to discuss medication changes with the pharmacist while Colombian patients had more
47 discussions with their doctor. Jamaicans had a higher odds of medium/low adherence
48 compared to Colombians (OR: 6.78 (95% CI: 3.91, 11.75) after adjusting for
49 sociodemographic factors and health care experiences. Further exploration of health system

50 issues that may explain these differences can inform strategies to improve medication
51 adherence in the region.

52 **Introduction**

53 Hypertension is a major risk factor for cardiovascular disease, chronic kidney disease, and
54 dementia (1, 2). It is estimated that hypertension is responsible for 8.5 million deaths globally,
55 88% of which take place in low and middle-income countries (LMICs) (2).

56

57 The 2016-17 National Jamaica Health and Lifestyle Survey reported a hypertension
58 prevalence of 34% (blood pressure (BP) \geq 140/90 mmHg and/or taking medications for
59 hypertension), with only 59% of people with hypertension being aware of their diagnosis (3).
60 Of those with diagnosed hypertension, 70% were on treatment but only 31% of those on
61 treatment had a BP of \leq 140/90 mmHg (3). In Colombia, the May Measurement Month
62 Campaign conducted in 2019 reported a prevalence of hypertension of 28%, with
63 approximately two-thirds of participants aware of their condition and 60% receiving
64 antihypertensive treatment (4). Similar to Jamaica, 38% of those on treatment were controlled
65 (4).

66

67 LMICs generally have poor BP control rates, despite the availability of effective medications
68 for treating hypertension (5). Poor medication adherence, which includes failure to initiate
69 treatment, take medications as prescribed, and maintain long-term therapy contribute to these
70 low levels of BP control (6-8).

71

72 Several sociodemographic factors have been associated with poor medication adherence.
73 These include male sex, younger age (under 60 years old), being single or unemployed,
74 smoking, multi-morbidity, poor hypertension knowledge and depression (8-14). In countries
75 such as United States, Canada, and the United Kingdom, medication adherence is lower in
76 Black and Hispanic and other minority populations (14-16). While these factors can influence
77 medication adherence, the health systems (all the organizations, institutions and resources that
78 are responsible for managing health) also play a critical role in this outcome (14, 17).
79 Inadequate access to healthcare, medication availability and accessibility, long waiting times
80 and poor patient-provider communication have been associated with reduced medication
81 adherence (17). However, use of fixed dose combination therapies, full prescription coverage
82 and reduced copayments for healthcare services are associated with improved adherence (18,
83 19).

84

85 The aim of the Caribbean and South American Team Based Strategies to Control
86 Hypertension (CATCH) study is to evaluate the implementation of a team-based strategy to
87 improve hypertension management in Jamaica and Colombia. Both countries, located in the
88 Latin America and Caribbean Region, with predominantly Hispanic / Black populations, have
89 a high burden of hypertension with different systems for healthcare management (3, 20). In
90 Jamaica 50% of the population accesses healthcare through government clinics and health
91 facilities using paper-based health records and appointment systems. Care is free of charge at
92 point of service. However, healthcare in Colombia is delivered through practitioners

93 contracted by private institutions (or state-run institutions) that are contracted by government
94 through insurance companies to provide care to patients and use electronic medical records
95 and appointment systems. All Colombian citizens are enrolled in a public health insurance
96 plan that provides certain basic services and this can be supplemented with other plans.

97

98 In this paper, we present data from a quantitative survey conducted as part of the needs
99 assessment for the implementation of the CATCH Study. We explored self-reported
100 medication adherence in both countries and evaluated whether health care delivery systems
101 explained any observed differences, after adjusting for important sociodemographic
102 confounders.

103 **Materials and Methods**

104 *Recruitment and Data collection*

105 The overall design of the CATCH study needs assessment has been previously described (21).
106 Patients with hypertension ≥ 18 years old attending primary care clinics (10 in Jamaica and 4
107 in Colombia for at least a year were recruited between August 2021 and February 2022, during
108 the COVID-19 pandemic. Jamaican patients were recruited consecutively from the clinic
109 attendees on appointment days on which chronic disease visits were scheduled while
110 Colombian patients were selected from an electronic medical records system database.

111

112 Questionnaires were administered by telephone after obtaining verbal consent in the native
113 language of the participant. The questionnaire captured data on sociodemographic factors
114 (age, sex, marital status, education), the presence of co-morbidities (diabetes,
115 hypercholesterolemia, stroke, kidney disease, depression, anxiety) and hypertension
116 treatment experiences including wait time for services such as registration, to see the nurse,
117 doctor and to obtain medication (less than 30 minutes, 30-60 minutes, > 60 minutes) and
118 whether medication choices, changes or substitution were discussed with the physician or
119 pharmacists.

120

121 ***Hypertension knowledge***

122 Hypertension knowledge was evaluated using an 18-item questionnaire that included 10
123 questions about risk factors for hypertension (role of diet, exercise, sleep, emotions, family
124 history), 6 on hypertension related outcomes (cardiovascular diseases, kidney disease and
125 dementia) and 2 on aspects of treatment knowledge (use of medications and need for long
126 term therapy).

127

128 ***Medication Adherence Measurement***

129 Adherence to antihypertensive medication was measured using the IMPACT- Medication
130 Adherence Scale (MAS). The IMPACT-MAS scale consists of two questions: “Over the last
131 7 days, on how many days did you not take any blood pressure pills?” (Maximum score of 4
132 if no medications are missed with lower scores as the number of days increases, 0 if none

133 were taken for all 7 days) and “Over the last 7 days, on how many days did you cut back (or
134 not take the full dose) of your blood pressure pills?” (Maximum score of 2 if medications
135 were taken as prescribed and 0 if reduction took places for all 7 days) with a total score
136 calculated based on the response. Patients were classified as having high (Score = 6), medium
137 (5 or 5.5) and low adherence <5 (22).

138

139 Ethical Approval for this study was obtained from the University of West Indies, the Ministry
140 of Health and Wellness and Southeast Regional Health Authority Ethics Committees in
141 Jamaica, Tulane University Institutional Review Board, USA and the Institutional Bioethics
142 Committee of Universidad de Santander, Colombia.

143

144 *Statistical analysis*

145 Weighted prevalence estimates were calculated for each country. Differences in percentages
146 between Jamaica and Colombia were assessed using chi-square tests or the Fisher's exact test
147 depending on sample size. Medication adherence was the primary outcome of interest with
148 characteristics of persons with high medication adherence (outcome =0) compared to those
149 with low and medium medication adherence (outcome =1) in the logistic models. Country
150 was used as a proxy for healthcare systems. Multivariable logistic models were adjusted for
151 patient sociodemographic factors and patient experiences at their last clinic visit to determine
152 the independent effects of healthcare delivery systems on medication adherence category.
153 Odds ratios with 95% confidence intervals are presented for these effects.

154 **Results**

155 Of the 576 hypertensive patients who were interviewed, 12 patients with hypertension who
156 were not treated with antihypertensive medications were excluded from this analysis leaving
157 a sample of 281 Jamaicans and 283 Colombians.

158 Table 1 presents the sociodemographic and health characteristics of the survey participants by
159 country and medication adherence category (high vs medium/low). Jamaican patients were
160 more likely to report medium/low medication adherence than Colombian patients (49.3% v.
161 11.8%, $p < 0.001$). In Colombia, patients under 60 years (37% v. 18%, $p = 0.044$), who
162 reported never having been married (26% v. 4.6%, $p < 0.001$) were more likely to report
163 medium/low medication adherence. However, in Jamaica, none of the sociodemographic
164 characteristics), were associated with self-reported medication adherence. In both countries,
165 hypertension knowledge was not associated with medication adherence. In Jamaica, people
166 with a history of heart attack/heart disease were less likely to report medium/low medication
167 adherence (0.4% v. 6.0%, $p < 0.001$). None of the other medical conditions examined showed
168 significant associations with medication adherence in either country.

169

170 ***Healthcare Experiences that could impact Adherence***

171 Patient experiences at their most recent clinic visit in each country are presented in Table 2.
172 While a significantly lower percentage of patients in Jamaica compared to those in Colombia
173 reported their doctor discussing their BP treatment plan, (56.8% v. 73.5%, $p = 0.001$), they
174 were more likely to report their pharmacist discussing medication substitution (41.3% v. 7.8%,

175 p <0.001). Jamaican patients experienced longer wait times (≥ 30 minutes), for registration
176 (78.5% v. 16.6%, p <0.001), to see a physician (87.2% v. 7.7%, p <0.001) and to get their
177 medication (81.2% v. 16.6%, p <0.001).

178

179 ***Factors associated with Medication Adherence***

180 The final multivariable logistic regression models used to explore the effect of health systems
181 on the odds of low medication adherence are presented in Table 3. Jamaican patients were 7
182 times more likely to report medium/low medication adherence compared to Colombian
183 patients after adjusting for age, sex, urban-rural status, education, and hypertension
184 knowledge (OR: 6.78 (95% CI: 3.91, 11.75)). The odds of reporting medium/low medication
185 adherence was inversely associated with age in the multivariable models. Differences in
186 medication adherence were not explained by any of the healthcare experiences that patients
187 reported on their last visit to the clinic. Besides country, age was the only other significant
188 independent variable from multivariable analysis and was inversely associated with
189 medium/low medication adherence. Other factors, including sex, urban-rural status, education
190 level, hypertension knowledge and healthcare experiences did not show significant
191 associations with medication adherence.

192 **Discussion**

193 In our final multivariable analysis, after adjusting for age, sex, urban-rural status, education,
194 and hypertension knowledge, Jamaican patients were found to be seven times more likely to
195 report medium/low medication adherence compared to Colombian patients. The effect was
196 not attenuated by any of the commonly reported confounders examined. Age was the only
197 factor besides country that was inversely associated with low/medium medication adherence
198 in multivariable models with a lower odds of having low/medium medication adherence with
199 advancing age.

200

201 Jamaican patients experienced longer wait times for all clinic services. Medication adherence
202 was not associated with patient experiences with health systems, and this did not explain
203 country differences. In models that included experiences patients reported at the last clinical
204 encounter; the findings were essentially unchanged. None of the individual experiences were
205 independent determinants of medication adherence or able to explain country differences in
206 medication adherence that we demonstrated.

207

208 In bivariate analysis age and marital status were found to be associated with medication
209 adherence in Colombia only, with younger persons (< 60 years) and those who have never
210 been married and widowed having medium/low medication adherence. These findings are
211 consistent with factors reported to be associated with better medication adherence,

212 specifically among Hispanics (23-25). However, while other studies have found other factors
213 to be associated with low medication adherence (namely, hypertension knowledge, education
214 level, hypertension complications, female gender, and being unemployed), we did not
215 demonstrate these associations (26-28).

216

217 Patients in Jamaica with heart disease reported higher medication adherence, no associations
218 were seen with other chronic health conditions. It is possible that patients with heart disease
219 in Jamaica may receive additional support that helps improve adherence or that this condition
220 may affect their perception of risk and improve adherence. We did not see this association in
221 Colombia. Multimorbidity, which often results in increased pill burden and as a result poor
222 medication adherence, was also not associated with medication adherence in this study (29).

223

224 Currently in Jamaica care for chronic diseases in Government run clinics may be limited to
225 specific days of the week. Most clinics operate during working hours (8am to 4pm) and while
226 dates for appointment are given, there is no specific time blocks and patients are seen in the
227 order of arrival. Several measures are being initiated that may improve the long waiting times
228 and potential delays in care, including extending opening hours at larger clinics and electronic
229 health records system (to reduce time spent waiting for records to be retrieved). Additionally,
230 the development of a National Health insurance scheme, similar to what exists in Colombia,
231 could allow patients to access care through approved privately run health facilities which

232 provide a more controlled environment that facilitates patients scheduling visits at more
233 convenient times and obtaining care from a more consistent team of practitioners.

234

235 Medication distribution in Colombia is coordinated by the health insurance companies, who
236 directly contract with medication providers and pharmacies for distribution. Patients are
237 assigned to a pharmacy depending on insurance agreements with a specific provider and
238 proximity to that facility. In some instances patients can also elect to select another local
239 pharmacy for obtaining their medications if there is an agreement in place with their insurance
240 company. A permanent audit system from the government ensures that national insurers fulfill
241 their commitment to providing access and availability of medicines. While Jamaicans can
242 access drugs from any of the government-run pharmacies with no fee at point of service,
243 availability of prescribed medications and long wait times is often a challenge. Patients also
244 have the option of purchasing their medications through private pharmacies using a
245 government issued card which provides a subsidy on medications for specific chronic
246 illnesses issues including hypertension. The government of Jamaica has instituted the Quick
247 Prescript App that allows patients to submit their prescription by phone to the clinic
248 pharmacies to determine the availability of medications in advance and reduce pharmacy wait
249 (30).

250

251 Many approaches to healthcare delivery in Colombia (including the use of electronic health
252 records system, a national health insurance scheme with universal coverage for chronic

253 illnesses such as hypertension, allowing patients to access to a mix of private and public
254 institution providers and health facilities) may also help to improve medication adherence in
255 Jamaican patients. In addition, improving healthcare provider - patient communication in both
256 settings may also improve medication adherence and hypertension control. Some of these
257 issues will be addressed in the CATCH study which aims at improving hypertension control
258 in both settings.

259

260 Strengths and Limitations

261 Limitations of the study include the use of self-report for evaluation of medication adherence.
262 We also did not measure BP or extract data from the medical records of respondents to
263 determine the BP control. We cannot be certain as to whether any differences in adherence
264 are related to cultural beliefs in both countries. The restrictions on face-to- face data collection
265 due to the COVID-19 pandemic resulting in data collection by telephone did not allow us to
266 ask additional questions that explored other issues affecting adherence such as transportation
267 barriers including cost, safety concerns (particularly in the clinics in some inner-city
268 communities), family support, polypharmacy and medication availability or access to
269 combination therapy.

270 .

271 We included a representative sample of patients obtaining care in each setting which provided
272 us with data to conduct this cross-country comparative study of hypertension care in Latin
273 America and the Caribbean. We were able to adjust for known confounders reported from

274 previous studies such as such as age, sex, and health insurance access to explore the
275 independent effect of the health system on the outcome of interest.

276 **Conclusions**

277 Understanding the health system factors that influence medication adherence is critical to
278 improving hypertension control. Future research should include qualitative exploration of
279 these findings and the evaluation of system factors that may contribute to these differences
280 between Colombia and Jamaica. The CATCH study has been designed to address some
281 barriers to medication adherence including addressing beliefs about BP and the medications
282 used for treatment, communication with healthcare providers, team-based approaches to care
283 and improving access to a simplified BP treatment algorithm with combination therapies.
284 Systems change with engagement of providers, patients and administrators can strengthen
285 medication adherence in both settings. Lessons from this experience will also be helpful to
286 other LMICs and High Income Countries such as the United States, when optimizing
287 hypertension treatment and control.

288

289 **Data Availability Statement:** The original contributions presented in the study are included
290 in the article; further inquiries can be directed to the corresponding author.

References

1. Singh S, Shankar R, Singh GP. Prevalence and Associated Risk Factors of Hypertension: A Cross-Sectional Study in Urban Varanasi. *International Journal of Hypertension*. 2017;2017:1-10.
2. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. *Nature Reviews Cardiology*. 2021;18(11):785-802.
3. Younger-Coleman N, Webster-Kerr K, Ferguson T, McFarlane S, Grant A, Bennett N, et al. Jamaica Health and Lifestyle Survey III (2016-2017). 2024.
4. Lopez-Jaramillo P, Lopez-Lopez JP, Otero J, Alarcon-Ariza N, Mogollon-Zehr M, Camacho PA, et al. May Measurement Month 2019: an analysis of blood pressure screening results from Colombia. *European Heart Journal Supplements*. 2021;23(Supplement_B):B46-B8.
5. Irazola VE, Gutierrez L, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gaziano T, et al. Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. *Global heart*. 2016;11(1).
6. Burnier M, Egan BM. Adherence in Hypertension. *Circulation Research*. 2019;124(7):1124-40.
7. Chen MJ, Wu CC, Wan LH, Zou GY, Neidlinger SH. Association Between Medication Adherence and Admission Blood Pressure Among Patients With Ischemic Stroke. *J Cardiovasc Nurs*. 2019;34(2):E1-E8.
8. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. *Curr Opin Cardiol*. 2004;19(4):357-62.
9. Noreen N, Bashir F, Khan AW, Safi MM, Lashari WA, Hering D. Determinants of Adherence to Antihypertension Medications Among Patients at a Tertiary Care Hospital in Islamabad, Pakistan, 2019. *Prev Chronic Dis*. 2023;20:E42.
10. Choi HY, Oh IJ, Lee JA, Lim J, Kim YS, Jeon T-H, et al. Factors Affecting Adherence to Antihypertensive Medication. *Korean Journal of Family Medicine*. 2018;39(6):325-32.
11. Alsofyani MA, Aloufi AO, Al-Qhtani NS, Bamansour SO, Almathkori RS. Factors related to treatment adherence among hypertensive patients: A cross-sectional study in primary healthcare centers in Taif city. *J Family Community Med*. 2022;29(3):181-8.
12. Asgedom SW, Atey TM, Desse TA. Antihypertensive medication adherence and associated factors among adult hypertensive patients at Jimma University Specialized Hospital, southwest Ethiopia. *BMC Research Notes*. 2018;11(1).

13. Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, Mcglynn EA, et al. Depression and Medication Adherence in the Treatment of Chronic Diseases in the United States: A Meta-Analysis. *Journal of General Internal Medicine*. 2011;26(10):1175-82.
14. Lee GKY, Wang HHX, Liu KQL, Cheung Y, Morisky DE, Wong MCS. Determinants of Medication Adherence to Antihypertensive Medications among a Chinese Population Using Morisky Medication Adherence Scale. *PLoS ONE*. 2013;8(4):e62775.
15. Asiri R, Todd A, Robinson-Barella A, Husband A. Ethnic disparities in medication adherence? A systematic review examining the association between ethnicity and antidiabetic medication adherence. *PLOS ONE*. 2023;18(2):e0271650.
16. Xie Z, St. Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately insured patients in the United States. *PLOS ONE*. 2019;14(2):e0212117.
17. Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication Adherence: Truth and Consequences. *The American Journal of the Medical Sciences*. 2016;351(4):387-99.
18. Kvarnström K, Westerholm A, Airaksinen M, Liira H. Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research. *Pharmaceutics*. 2021;13(7):1100.
19. Banerjee A, Khandelwal S, Nambiar L, Saxena M, Peck V, Moniruzzaman M, et al. Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. *Open Heart*. 2016;3(2):e000438.
20. Barrera L, Gómez F, Ortega D, Corhuelo J, Méndez F. Prevalence, awareness, treatment and control of high blood pressure in the elderly according to the ethnic group. Colombian survey. *Colombia Medica*. 2019:115-27.
21. Duncan JP, Geng S, Lindsay C, Ferguson T. S., Mills K. T., Lopez-Lopez J. P., He H, Lanza P, Marshall A. N., Williams M. J., Tonwe V, Reyes M, Campo A, Lopez-Jaramillo P, & Tulloch-Reid, M. K. Differences in COVID-19 Vaccination and Experiences among Patients with Hypertension in Colombia and Jamaica during the COVID-19 Pandemic. *International Journal of Environmental Research and Public Health*. 2024.
22. Allouch F, Peacock E, Mills KT, Whelton PK, Chen J, He J. A Novel Two-Question Antihypertensive Medication Adherence Scale Predicts Blood Pressure Control and Cardiovascular Disease Outcomes. *AHA Journals*; 2023.
23. Farah R, Alawwa I, Khateeb D, Hwidi B, Albdour K, Bani Monia O, et al. Factors Affecting the Level of Adherence to Hypertension Medications: A Cross-Sectional Study Using the Hill-Bone Questionnaire. *Patient Preference and Adherence*. 2024;Volume 18:893-904.

24. Gavrilova A, Bandere D, Rutkovska I, Šmits D, Mauriņa B, Poplavska E, et al. Knowledge about Disease, Medication Therapy, and Related Medication Adherence Levels among Patients with Hypertension. *Medicina*. 2019;55(11):715.
25. Bandi P GE, Parikh NS, Farsi P, Boden-Albala B. Age-Related Differences in Antihypertensive Medication Adherence in Hispanics: A Cross-Sectional Community-Based Survey in New York City, 2011–2012. *Prev Chronic Dis*. 2017;14.
26. Lor M, Koleck TA, Bakken S, Yoon S, Navarra A-MD. Association Between Health Literacy and Medication Adherence Among Hispanics with Hypertension. *Journal of racial and ethnic health disparities*. 2019;6(3).
27. Wan J, Wu Y, Ma Y, Tao X, Wang A. Predictors of poor medication adherence of older people with hypertension. *Nursing Open*. 2022;9(2):1370-8.
28. Mebrahtu G, M Moleki M, Okoth Achila O, Seyoum Y, Adgoy ET, Ovberedjo M. Antihypertensive Medication Adherence and Associated Factors: A Cross-Sectional Analysis of Patients Attending a National Referral Hospital in Asmara, Eritrea. *Patient Preference and Adherence*. 2021;Volume 15:2619-32.
29. Farrell B, French Merkley V, Ingar N. Reducing pill burden and helping with medication awareness to improve adherence. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2013;146(5):262-9.
30. Jamaica NHF-Go. Quick Prescript <https://www.nhf.org.jm/nhf-quick-prescript/>

291 **Acknowledgements:** We thank the patients and health center staff and the administration of
 292 Jamaica and Colombia, as well as the members of the CATCH team for their support in
 293 executing this study.

294 **Author Contributions:** Conceptualization, M.K.T.-R., S.L., T.F., P.L.-J.; methodology,
 295 M.K.T.-R., S.L., C.L., P.L., F.A, J.D., software, S.G. and .; validation, all authors; formal
 296 analysis, S.G. and L.S.; investigation, C.L. and P.L.; resources, M.W., V.T., P.L.-J. J.H.
 297 and M.K.T.-R.; data curation, S.G.; writing—original draft preparation, S.L. and
 298 M.K.T.-R.; writing—review and editing, all authors; visualization, all authors;
 299 supervision, M.K.T.R., J.D., J.L.-L., P.L., F.A., N.B., G.S-V., G.A-M.; project

300 **administration, M.K.T.-R.; CL, J.H, P.L.-J., M.W., V.T.; funding acquisition, M.W.,**
301 **V.T., P.L.-J. and M.K.T.-R. All authors have read and agreed to the published version of**
302 **the manuscript.**

303 **Funding:** This study was funded by the National Heart, Lung, and Blood Institute, grant
304 number UG3/UH3HL152373

305

306 **Ethical Approval**

307 This study was conducted in accordance with the Declaration of Helsinki and approved by
308 the Institutional Review Board of Tulane University (12 August 2022; 2022-980, Institutional
309 Bioethics Committee of Universidad de Santander in Colombia (16 July 2020; VII-050-BUC)
310 and the University of the West Indies (UWI) Mona Campus Research Ethics Committee in
311 Jamaica (30 June 2020; CREC-MN.0347)

312

313 **Competing Interests:** The authors declare no conflicts of interest. The funders had no role in
314 the design of the study; in the collection, analyses, or interpretation of data; in the writing of
315 the manuscript; or in the decision to publish the results.

316

317 **Tables**

318

319 **Figures:** There are no figures for this publication

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Table1JournalofHumanHypertensionFinal.pdf](#)
- [Table2JournalofHumanHypertensionFinal.pdf](#)